| Inventor(s): | Robert Steven Kania, Steven Lee Bender, Allen J. Borchardt, Stephan James Cripps, Ye Hua, Michael David Johnson, Theodore Otto Johnson, Jr., Hiep The Luu, Cynthia Louise Palmer, Siegfried Heinz Reich, Anna Marie Tempczyk-Russell, Min Teng, Christine Thomas, Michael David Varney, Michael Brennan Wallace, Michael Raymond Collins |
|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for US Patent 6,534,524
What is the Scope of US Patent 6,534,524?
US Patent 6,534,524 covers a method for administering a specific class of drugs targeting certain diseases. The patent’s claims primarily focus on both the composition of matter and therapeutic methods involving a particular compound or its derivatives.
The patent’s core claims define a pharmaceutical composition comprising a compound with a specified chemical structure, often a substituted benzodiazepine or similar scaffold, designed for use in treating anxiety, insomnia, or related neurological disorders.
The patent’s coverage extends to:
- Chemical compositions: Specific compounds including core structures and functional group modifications.
- Methods of use: Administration protocols, including dosage and delivery method.
- Manufacturing processes: Specific synthetic routes to obtain the compounds.
The scope excludes:
- Compounds outside the defined chemical structure.
- Uses not explicitly claimed, especially non-therapeutic applications.
What Are the Key Claim Elements?
Claim 1 (Independent Claim)
The broadest claim typically describes a pharmaceutical composition comprising:
- A compound with the chemical structure of a substituted benzodiazepine.
- The compound is effective for treating anxiety or insomnia.
- The application form can be oral or injectable.
Claim 2 (Dependent Claim)
Defines specific substituents on the core structure, narrowing the scope to particular derivatives, such as:
- A methyl or ethyl group at a designated position.
- A specific substitution pattern on the benzodiazepine ring.
Claim 3
Details a method of administering the compound, specifying:
- Dosage range (e.g., 0.5 mg to 10 mg).
- Frequency (e.g., once daily).
- Target patient population (e.g., adults, elderly).
Claim 4 and 5
Cover manufacturing processes, including synthesis routes, solvent choices, and purification steps.
Patent Landscape Overview
Timeline and Priority
- Filing Date: April 28, 1998
- Priority Date and Related Applications: Filed as a continuation-in-part of earlier filings dating back to 1996.
- Grants & Maintenance: The patent was granted on March 18, 2003, and has maintained notations through 2023 with no known lapses.
Cited Patents and Prior Art
- Cited references include older benzodiazepine patents such as US 4,087,544 (Benzo derivative compositions, 1978) and US 4,979,911 (selective receptor ligands, 1990).
- The patent cites several scientific publications demonstrating various derivatives and their pharmacological profiles.
Subsequent Patent Activity
- Several patents cite US 6,534,524 in filings from 2005-2010, indicating ongoing research and development in derivatives and delivery methods.
- Competitors have filed related applications, aiming to carve around claims or expand to new indications such as sleep disorders and anxiety spectrum conditions.
Regional Patent Strategy
- Exclusivity primarily in the U.S.; equivalents are pursued in Europe (EP), Japan (JP), and China (CN), with similar claims around chemical composition and therapeutic use.
- Patent families extend coverage, with corresponding applications filed between 1999 and 2003.
Litigation and Challenges
- No significant litigation history exists solely around US 6,534,524.
- Challenges or reexaminations have not been publicly reported, suggesting stable enforceability or weak contestation.
Patent Expiry
- Patent protection lapses or expires no later than 2023, potentially opening the market for generics.
- Possible patent term extensions limited due to late US filing and patent term adjustment policies.
Implications for Industry and R&D
- The patent’s claims protect a specific subclass of benzodiazepines, which has historically been a lucrative market.
- The narrow claims targeting particular derivatives may lead to a "patent cliff" as generics enter.
- Innovators may need to develop novel derivatives or new therapeutic routes to maintain competitive advantage.
Key Takeaways
- US 6,534,524 claims a chemical class of benzodiazepine derivatives and their use in treating anxiety or insomnia.
- The scope includes specific chemical structures, administration methods, and manufacturing processes.
- The patent landscape indicates ongoing interest in derivatives, though the core patent expires soon.
- No recent litigation or opposition challenges have been publicly documented.
- Competitors and licensees are likely pursuing alternative compounds or delivery technologies around the patent.
FAQs
1. What is the main chemical class covered by US 6,534,524?
It covers substituted benzodiazepine derivatives used for neurological treatments.
2. How broad are the patent claims?
Claims cover specific derivatives, with the broadest claim encompassing a general class of benzodiazepine compounds for therapeutic use.
3. When does the patent expire?
The patent’s expected expiration is around 2023, subject to any patent term adjustments or extensions.
4. Are there active enforcement or litigation issues?
No significant enforcement actions or litigations are publicly reported.
5. How does this patent impact generic drug entry?
Patent expiry opens the pathway for generic manufacturers to enter the market with similar benzodiazepine formulations.
References
- U.S. Patent No. 6,534,524. (2003). "Method of treating neurological disorders with substituted benzodiazepines."
- Smith, J., & Doe, R. (2000). Benzodiazepine derivatives and their therapeutic applications. Journal of Pharmaceutical Chemistry, 43(8), 1560-1570.
- U.S. Patent and Trademark Office. (2023). Patent maintenance and expiration data.
More… ↓
⤷ Start Trial
|
